NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 D-cycloserine and Lurasidone, an oral, fixed dosed combination of D-cycloserine/lurasidone that earned food and drug administration-designated as breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 ketamine, which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior ASIB. The company has a partnership with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

NRX Pharmaceuticals Inc.

The Vanguard Total Stock Market ETF (VTI) gives investors broad exposure to the entire U.S. stock market. In today’s VTI snapshot, we look at the f...

Vanguard Total Stock Market ETF (VTI) Daily Update—12/09/25

Austin, Texas, United States, December 3rd, 2025, FinanceWire NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said ...

NRx Pharmaceuticals (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment

The Vanguard Total Stock Market ETF ($VTI) gives investors wide access to big, mid-sized, and small U.S. companies—essentially covering the entire ...

VTI ETF Daily Update—12/03/2025

Austin, Texas, United States, December 1st, 2025, FinanceWire NRx Pharmaceuticals (NASDAQ: NRXP) Founder, Chairman and CEO Jonathan Javitt, M.D., M...

NRx Pharmaceuticals (NASDAQ: NRXP) to Present at NobleCon21

The Vanguard Total Stock Market ETF ($VTI) offers investors broad exposure to the entire U.S. equity market. In today’s VTI ETF snapshot, we break ...

VTI ETF Daily Update — 11/28/2025

The Vanguard Total Stock Market ETF ($VTI) provides broad exposure to large-, mid-, and small-cap U.S. companies, giving investors a stake in the f...

VTI ETF Daily Update—11/27/2025

The Vanguard Total Stock Market ETF ($VTI) offers broad exposure to large-, mid-, and small-cap U.S. companies, giving investors a stake in the ful...

VTI ETF Daily Update — November 21, 2025

What’s Moving VTI ETF? Daily Snapshot — 11/18/2025

Nrx Pharmaceuticals, Inc. ( ($NRXP) ) has released its Q3 earnings. Here is a breakdown of the information Nrx Pharmaceuticals, Inc. presented to i...

Market Cap	$66.03M	P/E Ratio	N/A
52W High	$6.01	52W Low	$1.15
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	N/A	52W Position	18.9%
Overall Score	28	Value Score	40
Quality Score	26	Technical Score	20

EPS Current Est	$-1.41	EPS Next Est	$0.19
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NRXP	$2.07	-5.91%	588.35K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NRXP	$2.07	-5.9%	588.35K
3
4
5
6

NRXP

NRXP

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get NRX Pharmaceuticals Inc. Data in Excel

Get NRX Pharmaceuticals Inc. Data in Excel